- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Procept Biorobotics Corp(PRCT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PRCT
11/13/2026: PRCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Procept Biorobotics is a specialized medical technology company that provides the AquaBeam Robotic System, a platform for minimally invasive BPH treatment. The company benefits from a strong recurring revenue model fueled by single-use consumables and a growing base of system placements. Its main growth opportunity lies in capturing market share from legacy urological procedures through better patient outcomes. Key risks include intense competition from established large-cap medical device firms, the necessity for continued successful execution of its sales strategy, and ongoing cash burn as it scales. The stock is best suited for growth-oriented investors who can tolerate volatility and are monitoring for consistent movement toward profitability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in a rapid scaling phase with high revenue growth potential in the urology market. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts strongly to news regarding clinical milestones or expansion, fitting a momentum-based strategy. |
| Value investor | Weak fit | Current valuation reflects growth expectations and does not align with traditional value-based metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | The company's status as a pre-profit, high-growth entity entails significant stock price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | High-growth medical stocks often experience significant price swings based on quarterly performance and sentiment. |
| Valuation risk | Medium / high | Investors pay a premium for growth, which can lead to rapid price corrections if growth targets are missed. |
| Competition risk (Urology Devices) | High | Major competitors with vast resources may introduce new treatments that threaten the AquaBeam's market share. |
| Business quality | Medium | While the technology is highly rated, the company is still establishing the long-term consistency of its business model. |
| Dividend income | Low / none | This investment is not suitable for those seeking regular income. |
| Execution risk | Medium / high | Scaling a surgical robotics business requires effective sales execution and consistent physician training. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37B USD | Price to earnings Ratio - | 1Y Target Price 22.75 |
Price to earnings Ratio - | 1Y Target Price 22.75 | ||
Volume (30-day avg) 1.3M shares | Beta 0.84 | 52 Weeks Range 16.66 - 38.11 | Updated Date 11/14/2026 |
52 Weeks Range 16.66 - 38.11 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -9.56% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Capital Equipment | Sale of the AquaBeam Robotic System units to hospitals and surgical centers. | This is the 'razor' part of the business; it provides the platform for recurring revenue. |
| Consumables & Services | Single-use handpieces for Aquablation and multi-year service contracts. | This is the 'blade' part of the business; it drives the margin growth and recurring cash flow. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.23B | Price to Sales(TTM) 3.83 |
Enterprise Value 1.23B | Price to Sales(TTM) 3.83 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA -24.58 | Shares Outstanding 57.54M | Shares Floating 55.97M |
Shares Outstanding 57.54M | Shares Floating 55.97M | ||
Percent Insiders 3.88 | Percent Institutions 95.71 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

